Search

Pimobendan

Ammonium tetrathiomolybdate

Tricetin

Hycanthone

Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.

COCAINE ESTERASE (RBP-8000)

RBP-8000 is under investigation in clinical trials (A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse) for the treatment of Cocaine

R1626

It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effective in inhibiting viral replication … R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors.

BW-A 58C

metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27. … BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy

Aclerastide

Aclerastide has been investigated for the treatment of Diabetic Foot, Diabetic Foot Ulcers, and Foot Ulcer, Diabetic.

Safimaltib

Safimaltib is a small molecule drug. Safimaltib is under investigation in clinical trial NCT06788509 (A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring).

Clesacostat

Clesacostat is under investigation in clinical trial NCT04321031 (Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)).